子宮内膜癌は子宮の悪性腫瘍であり、閉経後の出血の一般的な症状のために、早期に診断されることが多くなっています。早期診断率のため、手術は患者の先行治療の選択肢であり、再発のリスクが高い患者のみが化学療法またはホルモン療法による補助療法の対象と見なされます。子宮内膜癌に関連するアンメットニーズは、先行治療を受けた患者が再発した場合に生じるもので、進行した患者や再発した患者に使用できる治療法が不足しています。むしろ、ガイドラインでは、これらの患者に有効であることが示されているものの、現在は承認されていない多くの適応外治療が推奨されています。その結果、これらの患者は、厳しい診療報酬規制によってさらに制限されることになります。これまで子宮内膜癌は、ホルモンが原因で発症するものとそうでないものに分類されていましたが、新たなバイオマーカーが試験・承認されたことにより、複数のパイプライン薬剤が検討されています。GlobalData社は、2020年から2030年までの予測期間中に8主要市場において、合計5社の新規参入企業が発売すると予想しています。
目次
Table of Contents
1 Endometrial Cancer: Executive Summary
1.1 Large Market Growth Forecast for the Endometrial Cancer Market During 2020-2030
1.2 Immunotherapy Set to Become the Standard of Care and Redefine Patient Segmentation
1.3 Launches of Novel Therapies Will Significantly Address the Current Lack of Approved Therapies and Patient Segmentation
1.4 Immunotherapy and Novel Drug Classes to Lead the Endometrial Cancer Market
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Global and Historical Trends
4.3 Risk Factors and Comorbidities
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Incident Cases of Endometrial Cancer
4.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis
4.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype
4.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker
4.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
4.5 Epidemiological Forecast for Endometrial Cancer (2020-2030)
4.5.1 Diagnosed Incident Cases of Endometrial Cancer
4.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer
4.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
4.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype
4.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers
4.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
4.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Lack of Approved Therapies and Established Treatment Guidelines for Recurrent Patients
7.3 Establish Tumor Sequencing as Standard of Care
7.4 Define Patients Groups that Would Benefit from Maintenance Therapy
7.5 Treatment Alternatives for Patients who Cannot Tolerate Chemotherapy or Have Become Chemo-Resistant
8 R&D Strategies
8.1 Overview
8.1.1 Identify Optimal Immunotherapy Combination Strategies and Define Preferred Treatment per Line of Therapy
8.1.2 Introduction of Novel Mechanisms of Action and Targets
8.2 Clinical Trial Design
8.2.1 Precedent for EC Clinical Trial Design and Importance for Ongoing Clinical Trials
8.2.2 Limitations of Current Clinical Trials
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 PD-1/PD-L1 Inhibitors Plus Chemotherapy Under Investigation with a Maintenance Component
9.2.2 PD-1/PD-L1 Inhibitor Combinations with Either Chemotherapy or Targeted Therapies, Without a Maintenance Component
9.2.3 Novel Drug Classes Targeting the Unresectable and Relapsed Population
9.2.4 Promising Novel Therapies in Early-Stage Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
13 Appendix
List of Tables
Table 1: Endometrial Cancer: Key Metrics in the 8MM
Table 2: Stage Definitions for Endometrial Cancer
Table 3: Risk Factors for Endometrial Cancer
Table 4: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Subtype, Women, Ages 18 Years, N, 2020
Table 5: Treatment Guidelines for Endometrial Cancer
Table 6: Endometrial Cancer Market - Global Drivers and Barriers, 2020-2030
Table 7: Key Events Impacting Sales for EC in the US, 2020-2030
Table 8: EC Market - Drivers and Barriers in the US, 2020-2030
Table 9: Key Events Impacting Sales for EC in the 5EU, 2020-2030
Table 10: EC Market - Drivers and Barriers in the 5EU, 2020-2030
Table 11: Key Events Impacting Sales for EC in Japan, 2020-2030
Table 12: Endometrial Cancer Market - Drivers and Barriers in Japan, 2020-2030
Table 13: Key Events Impacting Sales for EC in Canada, 2020-2030
Table 14: EC Market - Drivers and Barriers in Canada, 2020-2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Endometrial Cancer in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Endometrial Cancer During the Forecast Period
Figure 4: Impact of the Estrogen-Progesterone Cycle in Determining Endometrial Thickness
Figure 5: Prognostic Groups in Endometrial Cancer According to TCGA
Figure 6. 8MM, Diagnosed Incidence of Endometrial Cancer (Cases per 100,000 population), Women, Ages ?18 Years, 2020 and 2030
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by Subtype
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
Figure 13: Diagnosed Incident Cases of Endometrial Cancer, 8MM, Women, Ages ?18 years, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Age, Women, N, 2020
Figure 15: 8MM, Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage, Women, Ages ?18 Years, N, 2020
Figure 16: 8MM, Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker, Women, Ages ?18 Years, N, 2020
Figure 17: 8MM, Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage, Women, Ages ?18 Years, N, 2020
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ?18 Years, N, 2020
Figure 19: Treatment Overview for Endometrial Cancer
Figure 20: Unmet Needs and Opportunities in Endometrial Cancer
Figure 21: Projected Treatment Decisions to Determine Use of Various Pipeline Agents in the First-Line Setting
Figure 22: Overview of the Development Pipeline in Endometrial Cancer
Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Endometrial Cancer in the 8MM During the Forecast Period
Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, chemotherapy
Figure 25: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period
Figure 26: Global (7MM) Sales Forecast by Country for Endometrial Cancer in 2020 and 20230
Figure 27: Sales Forecast by Class for EC in the US in 2020 and 2030
Figure 28: Sales Forecast by Class for EC in the 5EU in 2020 and 2030
Figure 29: Sales Forecast by Class for EC in Japan in 2020 and 2030
Figure 30: Sales Forecast by Class for EC in Canada in 2020 and 2030
